Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Small study aims to unravel Statins' muscle side effects

NCT ID NCT02908425

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 36 times

Summary

This study looks at how statins, common cholesterol-lowering drugs, affect the body's handling of a substance called HMB, which is linked to muscle health. Researchers will study 13 older adults (ages 65-80) who take statins, measuring HMB levels in blood and urine. The goal is to understand why statins can cause muscle loss and find ways to prevent it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ELEVATED HMB EXCRETION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Texas A&M University CTRAL

    College Station, Texas, 77845-4253, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Beta Hydroxymethyl butyrate (HMB)

What this could lead to

If successful, this research could point toward new ways to prevent muscle loss in older adults taking statins.

What could go wrong

This is a small, early-stage study with only 13 participants, focused on understanding metabolism rather than testing a treatment. Results may not apply to everyone.

Conditions

The condition(s) this trial relates to.

beta-aminoisobutyric acid, urinary excretion of

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.